Tenax Therapeutics, Inc.
TENX· Nasdaq
TENXTenax Therapeutics, Inc.
Filed Aug 14, 2020 · 10-Q · 45 days after period end · 0001654954-20-009183
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Net Income | -$2.15M | $1.76M | $1.87M | $2.99M |
| EPS Diluted | -$0.23 | -$0.28 | -$1.28 | -$2.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
ended Jun 30, 2020 · filed Aug 14, 2020 · 45 d after period end
